Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

crowdsourcing

- PMLiVE

Almirall’s Klisyri receives expanded FDA approval to treat actinic keratosis

The precancerous condition is responsible for an estimated 60% of all squamous cell carcinoma cases

- PMLiVE

Almirall survey reveals limited knowledge of most common precancerous skin condition

An estimated 60% of squamous cell carcinoma cases, the second most common skin cancer, develop from AK lesions

- PMLiVE

Johnson & Johnson to expand dermatology portfolio with $850m Proteologix acquisition

The company will gain access to two treatments for atopic dermatitis

- PMLiVE

UK survey reveals two-thirds of vitiligo patients struggle with mental health

The Vitiligo Society has launched a campaign to address the lack of awareness and understanding surrounding the condition

- PMLiVE

Almirall gains rights to Eloxx’s rare dermatological disease asset in deal worth over $470m

ZKN-013 is designed to overcome nonsense mutations in rare skin diseases such as junctional epidermolysis bullosa

- PMLiVE

Pfizer’s Litfulo recommended by NICE as first treatment for severe alopecia areata

Up to 14,000 patients living with the autoimmune disease could benefit from NICE’s decision

- PMLiVE

Almirall gains rights to Novo Nordisk’s IL-21 blocker for dermatological diseases

NN-8828 has been developed up to phase 2 in non-dermatological indications

- PMLiVE

Almirall and CRG partner to advance therapeutic approaches for atopic dermatitis

The inflammatory skin disease currently affects an estimated 4.4% of adults in the EU

- PMLiVE

Almirall and Microsoft partner to accelerate digital transformation in medical dermatology

The alliance is aimed at advancing the research of solutions for dermatological diseases

- PMLiVE

Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis

More than 26 million people in the US are affected by the inflammatory skin disease

- PMLiVE

Bristol Myers Squibb’s Opdualag approved by MHRA for advanced melanoma

Approximately 17,000 cases of melanoma are diagnosed in the UK every year

- PMLiVE

Bristol Myers Squibb’s Sotyktu accepted by SMC for plaque psoriasis

More than 133,520 people in Scotland are affected by the inflammatory condition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links